Ji Yuan, Fan Long, Wu Gaohui, Ding Niu, Liu Cong, Wu Lei, Wang Lanxiang, Huang Donghui, Xu Damo, Xiao Xiaojun, Lin Lin, Liu Xiaoyu
Institute of Allergy & Immunology, Shenzhen Key Laboratory of Allergy and Immunology, State Key Laboratory of Respiratory Disease Shenzhen University Division, Shenzhen University School of Medicine, Shenzhen, China.
Shenzhen Institute for Drug Control (Shenzhen Testing Center of Medical Devices), Shenzhen, China.
J Thorac Dis. 2024 Sep 30;16(9):5981-5994. doi: 10.21037/jtd-24-398. Epub 2024 Sep 26.
As a novel immunomodulator, spleen aminopeptides (FUKETUO) can correct the imbalance of immune cells and elevate their functions. Spleen aminopeptides have been used in the treatment of respiratory diseases. However, the regulatory mechanism of it on allergic asthma and desensitization has not been reported, further study is critically needed. This study aimed to investigate the effect and mechanism of spleen aminopeptides on allergic asthma and desensitization. We established an allergic asthma model by house dust mite (HDM) with/without desensitization treatment.
The allergic asthma mouse model was established with HDM and treated with desensitization and increasing dose of spleen aminopeptides according to different immune phases. Pathological markers such as airway hyper-responsiveness, and cell composition were monitored to determine the effectiveness of treatment.
Spleen aminopeptides can promote the proportion of interleukin-10 positive (IL10) allergen-specific regulatory T cells (Tregs), and further promote interleukin-10 (IL-10) expression in desensitization. They alleviated the allergic symptoms and elevated desensitization, decreased airway hyper-reaction and lung tissue injury, reduced specific immunoglobulin E (IgE) in serum, eosinophil number and interleukin-4 (IL-4) expression in bronchoalveolar lavage fluid (BALF), therefore, being able to control allergic asthma.
Our results suggested that spleen aminopeptides (FUKETUO) could elevate the expression of (CD4CD25IL10) Tregs, especially when it co-immunized with desensitization. Thereby, FUKETUO improved the efficacy of desensitization, and inhibited the development of allergic asthma.
脾氨肽（复可托）作为一种新型免疫调节剂，可纠正免疫细胞失衡并提升其功能。脾氨肽已用于呼吸系统疾病的治疗。然而，其对过敏性哮喘及脱敏作用的调控机制尚未见报道，亟需进一步研究。本研究旨在探讨脾氨肽对过敏性哮喘及脱敏的作用及机制。我们通过屋尘螨（HDM）建立了有无脱敏治疗的过敏性哮喘模型。
用HDM建立过敏性哮喘小鼠模型，并根据不同免疫阶段进行脱敏及递增剂量脾氨肽治疗。监测气道高反应性和细胞组成等病理指标以确定治疗效果。
脾氨肽可促进白细胞介素-10阳性（IL10）过敏原特异性调节性T细胞（Tregs）比例增加，并在脱敏过程中进一步促进白细胞介素-10（IL-10）表达。它们减轻了过敏症状，提高了脱敏效果，降低了气道高反应性和肺组织损伤，降低了血清中特异性免疫球蛋白E（IgE）、支气管肺泡灌洗液（BALF）中嗜酸性粒细胞数量及白细胞介素-4（IL-4）表达，因此能够控制过敏性哮喘。
我们的结果表明，脾氨肽（复可托）可提高（CD4CD25IL10）Tregs的表达，尤其是与脱敏联合免疫时。由此，复可托提高了脱敏效果，并抑制了过敏性哮喘的发展。
